住院抗菌药物管理项目是否有助于对抗耐药菌?
结果显示ASP后抗生素总体使用下降,但耐万古霉素肠球菌感染率上升,其他重点耐药菌感染率无变化。提示ASP实施后2至6年内可能未见耐药菌感染率改善。
要点
- ASP实施后目标抗生素总体消耗下降,按DDD降6.1%,按DOT降4.3%。
- 产ESBL、耐碳青霉烯肠杆菌和多重耐药铜绿假单胞菌感染率无显著变化。
核心结论
- ASP成功减少目标抗生素消耗后,实施后2至6年内可能未见耐药菌感染率变化。
- 不同菌种和抗生素恢复敏感性的时间尺度可能不同, compensatory prescribing可能带来意外后果。
研究设计与样本
- 使用广义线性混合效应模型评估ASP对18种目标抗生素消耗的影响,并用多变量模型估计对耐药菌感染率的调整效应。
- 分析调整了时间、聚类效应以及患者和医院层面特征的混杂。
主要发现
- 按限定日剂量(DDD),ASP后抗生素总体使用下降6.1%(-7.5%至-4.7%)。
- 按治疗天数(DOT),ASP后抗生素总体使用下降4.3%(-5.4%至-3.1%)。
- ASP后处方数量增加(1.04 [1.03-1.05])。
- 调整分析中,ASP后耐万古霉素肠球菌感染总体增加(1.37 [1.10-1.69])。
- ASP后产ESBL、耐碳青霉烯肠杆菌和多重耐药铜绿假单胞菌感染率未检测到变化。
临床怎么用
- ASP减少目标抗生素消耗的成效不应仅以短期耐药菌感染率下降为唯一评价指标。
- 需关注ASP实施后可能出现的补偿性处方及耐万古霉素肠球菌感染增加。
局限性
- 为回顾性队列研究,可能存在未测量混杂。
- 随访时间为实施后2至6年,可能不足以观察到耐药菌感染率变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antibiotic stewardship programs (ASPs) have demonstrated success at reducing costs, yet there is limited quality evidence of their effectiveness in reducing infections of high-profile drug-resistant organisms. METHODS: This retrospective, cohort study included all Kaiser Permanente Southern California (KPSC) members aged ≥18 years hospitalized in 9 KPSC hospitals from 1 January 2008 to 31 December 2016. We measured the impact of staggered ASP implementation on consumption of 18 ASP-targeted antibiotics using generalized linear mixed-effects models. We used multivariable generalized linear mixed-effects models to estimate the adjusted effect of an ASP on rates of infection with drug-resistant organisms. Analyses were adjusted for confounding by time, cluster effects, and patient- and hospital-level characteristics. RESULTS: We included 765 111 hospitalizations (288 257 pre-ASP, 476 854 post-ASP). By defined daily dose, we found a 6.1% (-7.5% to -4.7%) overall decrease antibiotic use post-ASP; by days of therapy, we detected a 4.3% (-5.4% to -3.1%) decrease in overall use of antibiotics. The number of prescriptions increased post-ASP (1.04 [1.03-1.05]). In adjusted analyses, we detected an overall increase in vancomycin-resistant enterococci infections post-ASP (1.37 [1.10-1.69]). We did not detect a change in the rates of extended-spectrum beta-lactamase, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa infections post-ASP. CONCLUSIONS: ASPs with successful reductions in consumption of targeted antibiotics may not see changes in infection rates with antibiotic-resistant organisms in the 2 to 6 years post-implementation. There are likely differing timescales for reversion to susceptibility across organisms and antibiotics, and unintended consequences from compensatory prescribing may occur.
引用
- Tartof SY, Chen LH, Tian Y, et al. Do Inpatient Antimicrobial Stewardship Programs Help Us in the Battle Against Antimicrobial Resistance? Clin Infect Dis. 2021. PMID: 32667983. doi:10.1093/cid/ciaa1004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。